Immediate Impact
61 standout
Citing Papers
Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
2023 Standout
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
2023 Standout
Works of Bruce H. Gross being referenced
Assessing dangerousness and responding appropriately: Hedlund expands the clinician's liability established by Tarasoff.
1987
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Bruce H. Gross | 275 | 83 | 63 | 136 | 131 | 17 | 359 | |
| Ira K. Packer | 297 | 116 | 36 | 141 | 62 | 30 | 410 | |
| Kristen Roy‐Bujnowski | 257 | 95 | 108 | 156 | 101 | 16 | 391 | |
| Jean-Claude Lasry | 185 | 124 | 111 | 161 | 84 | 18 | 404 | |
| Kenneth L. Appelbaum | 212 | 66 | 43 | 105 | 89 | 26 | 308 | |
| F. Allodi | 289 | 43 | 101 | 133 | 39 | 25 | 373 | |
| Nahama Broner | 254 | 69 | 122 | 146 | 121 | 15 | 377 | |
| M. David Enoch | 186 | 49 | 63 | 43 | 117 | 19 | 409 | |
| Mari Anne Harty | 324 | 80 | 79 | 129 | 146 | 15 | 393 | |
| Natalie Bonfine | 206 | 101 | 113 | 67 | 65 | 27 | 300 | |
| Alan M. Goldstein | 244 | 84 | 30 | 86 | 52 | 14 | 358 |
All Works
Loading papers...